2012New England Journal of MedicineRequires access

Fingolimod for Multiple Sclerosis

Daniel Pelletier, David A. Hafler

Open publisher page 317 citations

Abstract

A 37-year-old man with multiple sclerosis has recurrent disease activity despite several previous therapies. Treatment with fingolimod is recommended. Fingolimod blocks the egress of lymphocytes from lymph nodes, preventing them from reaching the central nervous system.

About this research paper

What this paper is about

A 37-year-old man with multiple sclerosis has recurrent disease activity despite several previous therapies. Treatment with fingolimod is recommended. Fingolimod blocks the egress of lymphocytes from lymph nodes, preventing them from reaching the central nervous system.

Why it matters

OpenAlex reports 317 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

A 37-year-old man with multiple sclerosis has recurrent disease activity despite several previous therapies. Treatment with fingolimod is recommended. Fingolimod blocks the egress of lymphocytes from lymph nodes, preventing them from reaching the central nervous system.

Key concepts: Fingolimod, Medicine, Multiple sclerosis, Central nervous system, Relapsing remitting, Immunology, Internal medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
Fingolimod for Multiple Sclerosis — Research Paper | ScholarLens